Apellis Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $199,913 | $458,578 | $178,494 | $166,797 |
Gross Profit | 170,194 | 434,047 | 164,422 | 132,437 |
EBITDA | -47,464 | 227,935 | -30,087 | -80,389 |
EBIT | -47,791 | 227,596 | -30,533 | -80,835 |
Net Income | -58,951 | 215,715 | -42,151 | -92,225 |
Net Change In Cash | 199,913 | 458,578 | 178,494 | 166,797 |
Free Cash Flow | -13,971 | 108,320 | 4,396 | -53,418 |
Cash | 467,760 | 479,171 | 371,466 | 358,393 |
Basic Shares | 126,024 | 126,024 | 126,024 | 125,453 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $1,003,782 | $781,367 | $396,591 | $75,422 |
Gross Profit | 901,546 | 663,644 | 338,081 | 69,786 |
EBITDA | 69,995 | -154,528 | -495,211 | -617,390 |
EBIT | 68,437 | -156,325 | -496,915 | -618,877 |
Net Income | 22,388 | -197,878 | -528,628 | -652,172 |
Net Change In Cash | 1,003,782 | 781,367 | 396,591 | 75,422 |
Free Cash Flow | 45,014 | -88,269 | -595,508 | -515,269 |
Cash | 467,760 | 411,290 | 351,185 | 551,801 |
Basic Shares | 126,024 | 123,905 | 118,678 | 106,114 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.47 |
2025-09-30 | $1.67 |
2025-06-30 | -$0.33 |
